The effect of LMWH (Nadroparin) on tumor progression

Pathology and Oncology Research

Volumn 15, Issue 4, 2009, Pages 689-692

  Nagy, Zsuzsanna ^a   Turcsik, Vera ^b   Blaskó, György ^c  

^a Szent Imre Hospital   (Hungary)

^b Governmental Health Center   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

LMWH; Nadroparin; Survival; Tumor progression

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PACLITAXEL;

ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; HUMAN; OVARY CANCER; THROMBOEMBOLISM; TUMOR GROWTH;

ANTICOAGULANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COLONIC NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; LEUCOVORIN; MALE; NADROPARIN; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PILOT PROJECTS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 74949103246     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-009-9204-7     Document Type: Article

References (13)

1. S von Delius M Ayvaz S Wagenpfeil, et al. 2007 Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma Thromb Haemost 98 434 439
2. A Lazo-Lagner GD Goss JN Spaans, et al. 2007 The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials J Thrombosis Haemostasis 5 729 737 10.1111/j.1538-7836.2007.02427.x (Pubitemid 46563571)
3. AK Kakkar 2005 Low-molecular-weight heparin and survival in patients with malignant disease Cancer Control 12 22 30 16179901
4. EA Akl FF VanDoormaal M Barba, et al. 2008 Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review J Exp Clin Cancer Res 27 4 10.1186/1756-9966-27-4 18577254
5. AK Kakkar MN Levine Z Kadziola 2004 Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS) J Clin Oncol 22 1944 1948 10.1200/JCO.2004.10. 002 1:CAS:528:DC%2BD2cXptlCks74%3D 15143088 (Pubitemid 41095187)
6. J Tóvári B Bereczky R Gilly, et al. 2004 Effect of heparin treatment on the metastatization of melanoma in a preclinical model (in Hungarian) Magy Onkol 48 235 241 15520874
7. F De Lorenzo O Dotsenko MF Scully, et al. 2006 The Role of Anticoagulation in Cancer Patients: Facts and Figures Anti-Cancer Agents in Medical Chemistry 6 579 587 10.2174/187152006778699112 (Pubitemid 44697116)
8. CPW Klerk SM Smorenburg HM Otten, et al. 2005 The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy J Clin Oncol 23 2130 2135 10.1200/JCO.2005.03.134 1:CAS:528:DC%2BD2MXjsVyiurY%3D 15699479 (Pubitemid 46218704)
9. JP Li 2008 Heparin, heparan sulfate and heparanase in cancer: remedy for metastasis? Anti-Cancer Agents in Medical Chemistry 8 64 76 10.2174/ 187152008783330824
10. A Falanga M Marchetti 2007 Heparin in tumor progression and metastatic dissemination Semin Thromb Haemost 33 688 694 10.1055/s-2007-991536 1:CAS:528:DC%2BD2sXhsVGrtrzL (Pubitemid 350157013)
11. R Castelli F Porro P Tarsia 2004 The heparins and cancer: review of clinical trials and biological properties Vasc Med 9 205 213 10.1191/1358863x04vm566ra 15675186 (Pubitemid 40124086)
12. I Vlodavsky N Ilan Y Nadir, et al. 2007 Heparanase, heparin and the coagulation system in cancer progression Thromb Res 120 112 120 10.1016/S0049-3848(07)70139-1 (Pubitemid 350101779)
13. Casu B, Vlodavsky I, Sanderson RD (2009) Pathophysiol Haemost Thromb 2007-08: 36, 195-203, doi: 10.1159/000175157